It appears that short term price moments are irrelevant as price is frozen on a 7 cents average, which could point to an agreed entry price for partner to commit early 23 after rat tox trial for 3 days. That seems to have been one of the partners conditions to have additional insurance on tox references, one of the main concerns within industry.
Our recent top standard tox results would have triggered to pull forward those trials which usually occur at a later date during human trials. Understandably, partner leaves little to chance to move into an anticipated licence deal.
all IMO
Ann: Successful Toxicology Studies Pave Way for Human Trials, page-56
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $489.9M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.8¢ | 10.3¢ | $174.9K | 1.664M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 1219974 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 404496 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| PYC (ASX) Chart |